Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer

Siegel, 2021, Cancer statistics, CA A Cancer J. Clin., 71, 7, 10.3322/caac.21654 Eiber, 2020, 18)F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy, J. Nucl. Med., 61, 696, 10.2967/jnumed.119.234914 Swami, 2020, Advanced prostate cancer: treatment advances and future directions, Trends Canc., 6, 702, 10.1016/j.trecan.2020.04.010 Wang, 2018, Genetics and biology of prostate cancer, Genes Dev., 32, 1105, 10.1101/gad.315739.118 Siegel, 2020, Prostate cancer incidence and survival, by stage and race/ethnicity — United States, 2001–2017, MMWR Morb. Mortal. Wkly. Rep., 69, 1473, 10.15585/mmwr.mm6941a1 Grossman, 2018, Screening for prostate cancer: US preventive services task force recommendation statement, JAMA, 319, 1901, 10.1001/jama.2018.3710 Ge, 2020, Epigenetic modulations and lineage plasticity in advanced prostate cancer, Ann. Oncol., 31, 470, 10.1016/j.annonc.2020.02.002 Gandaglia, 2014, Distribution of metastatic sites in patients with prostate cancer: a population-based analysis, Prostate, 74, 210, 10.1002/pros.22742 Riihimäki, 2018, Clinical landscape of cancer metastases, Cancer Med., 7, 5534, 10.1002/cam4.1697 Pezaro, 2014, Visceral disease in castration-resistant prostate cancer, Eur. Urol., 65, 270, 10.1016/j.eururo.2013.10.055 Loriot, 2017, Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial, Cancer, 123, 253, 10.1002/cncr.30336 Tremont-Lukats, 2003, Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience, Cancer, 98, 363, 10.1002/cncr.11522 Bhambhvani, 2020, Prostate cancer brain metastases: a single-institution experience, World Neurosurg., 138, e445, 10.1016/j.wneu.2020.02.152 Macedo, 2017, Bone metastases: an overview, Onco Rev., 11, 321 Logothetis, 2005, Osteoblasts in prostate cancer metastasis to bone, Nat. Rev. Cancer, 5, 21, 10.1038/nrc1528 Sgouros, 2020, Radiopharmaceutical therapy in cancer: clinical advances and challenges, Nat. Rev. Drug Discov., 19, 589, 10.1038/s41573-020-0073-9 Li, 2019, Role of tumor-derived exosomes in bone metastasis, Oncol. Lett., 18, 3935 Das, 2019, Bringing prostate cancer germline genetics into clinical practice, J. Urol., 202, 223, 10.1097/JU.0000000000000137 Rubin, 2011, Common gene rearrangements in prostate cancer, J. Clin. Oncol., 29, 3659, 10.1200/JCO.2011.35.1916 Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat. Genet., 44, 685, 10.1038/ng.2279 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Nelson, 2017, 1 Taylor, 2010, Integrative genomic profiling of human prostate cancer, Cancer Cell, 18, 11, 10.1016/j.ccr.2010.05.026 Haffner, 2013, Tracking the clonal origin of lethal prostate cancer, J. Clin. Invest., 123, 4918, 10.1172/JCI70354 Baca, 2013, Punctuated evolution of prostate cancer genomes, Cell, 153, 666, 10.1016/j.cell.2013.03.021 Hieronymus, 2012, Traversing the genomic landscape of prostate cancer from diagnosis to death, Nat. Genet., 44, 613, 10.1038/ng.2301 Mateo, 2020, Genomics of lethal prostate cancer at diagnosis and castration resistance, J. Clin. Invest., 130, 1743, 10.1172/JCI132031 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Grasso, 2012, The mutational landscape of lethal castration-resistant prostate cancer, Nature, 487, 239, 10.1038/nature11125 Abida, 2017, 2017 Beltran, 2016, Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, Nat. Med., 22, 298, 10.1038/nm.4045 Stopsack, 2019, Aneuploidy drives lethal progression in prostate cancer, Proc. Natl. Acad. Sci. U. S. A., 116, 11390, 10.1073/pnas.1902645116 Hieronymus, 2018, Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death, Elife, 7, 10.7554/eLife.37294 Hieronymus, 2014, Copy number alteration burdeInt. J. Endocr. Oncol.n predicts prostate cancer relapse, Proc. Natl. Acad. Sci. U. S. A., 111, 11139, 10.1073/pnas.1411446111 Clermont, 2019, Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines, Int. J. Endocr. Oncol., 6 Ku, 2017, Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance, Science, 355, 78, 10.1126/science.aah4199 Berger, 2019, N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer, J. Clin. Invest., 129, 3924, 10.1172/JCI127961 Shah, 2019, PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma), Prostate, 79, 1267, 10.1002/pros.23831 Armstrong, 2016, PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy, Oncotarget, 7, 7885, 10.18632/oncotarget.6955 Zhang, 2018, Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance, Nature, 553, 91, 10.1038/nature25015 Calagua, 2021, A subset of localized prostate cancer displays an immunogenic phenotype Associated with losses of key tumor suppressor genes, Clin. Cancer Res., 27, 4836, 10.1158/1078-0432.CCR-21-0121 Deplus, 2017, TMPRSS2-ERG fusion promotes prostate cancer metastases in bone, Oncotarget, 8, 11827, 10.18632/oncotarget.14399 Weng, 2019, Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis, Oncogene, 38, 2005, 10.1038/s41388-018-0575-7 Stankiewicz, 2017, Identification of FBXL4 as a metastasis associated gene in prostate cancer, Sci. Rep., 7, 5124, 10.1038/s41598-017-05209-z van Dessel, 2019, The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact, Nat. Commun., 10, 5251, 10.1038/s41467-019-13084-7 Shiao, 2016, Regulation of prostate cancer progression by the tumor microenvironment, Cancer Lett., 380, 340, 10.1016/j.canlet.2015.12.022 Bonollo, 2020, The role of cancer-associated fibroblasts in prostate cancer tumorigenesis, Cancers, 12, 10.3390/cancers12071887 Chiarugi, 2014, Tumor microenvironment and metabolism in prostate cancer, Semin. Oncol., 41, 267, 10.1053/j.seminoncol.2014.03.004 Tuxhorn, 2002, Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling, Clin. Cancer Res., 8, 2912 Olumi, 1999, Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium, Cancer Res., 59, 5002 Thalmann, 2010, Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells, Eur. Urol., 58, 162, 10.1016/j.eururo.2009.08.026 Gabbiani, 2003, The myofibroblast in wound healing and fibrocontractive diseases, J. Pathol., 200, 500, 10.1002/path.1427 Levesque, 2018, Cellular constituents of the prostate stroma: key contributors to prostate cancer progression and therapy resistance, Cold Spring Harb. Perspect. Med., 8, 10.1101/cshperspect.a030510 Alkasalias, 2018, Fibroblasts in the tumor microenvironment: shield or spear?, Int. J. Mol. Sci., 19, 1532, 10.3390/ijms19051532 Yang, 2017, Stromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer, Dis. Model. Mech., 10, 39 Chen, 2021, Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression, Nat. Cell Biol., 23, 87, 10.1038/s41556-020-00613-6 Blagosklonny, 2002, Oncogenic resistance to growth-limiting conditions, Nat. Rev. Cancer, 2, 221, 10.1038/nrc743 Polyak, 2009, Co-evolution of tumor cells and their microenvironment, Trends Genet., 25, 30, 10.1016/j.tig.2008.10.012 Josson, 2010, Tumor-stroma co-evolution in prostate cancer progression and metastasis, Semin. Cell Dev. Biol., 21, 26, 10.1016/j.semcdb.2009.11.016 Sung, 2008, Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis, Cancer Res., 68, 9996, 10.1158/0008-5472.CAN-08-2492 DiNatale, 2019, The bone microenvironment in prostate cancer metastasis, Adv. Exp. Med. Biol., 1210, 171, 10.1007/978-3-030-32656-2_9 Lin, 2020, The bone extracellular matrix in bone formation and regeneration, Front. Pharmacol., 11, 757, 10.3389/fphar.2020.00757 Deville, 2019, The extracellular, cellular, and nuclear stiffness, a trinity in the cancer resistome-a review, Front. Oncol., 9, 1376, 10.3389/fonc.2019.01376 Pang, 2019, Identification of SPP1 as an extracellular matrix signature for metastatic castration-resistant prostate cancer, Front. Oncol., 9, 924, 10.3389/fonc.2019.00924 Tang, 2020, Role of αVβ3 in prostate cancer: metastasis initiator and important therapeutic target, OncoTargets Ther., 13, 7411, 10.2147/OTT.S258252 Hall, 2008, Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase, Neoplasia, 10, 797, 10.1593/neo.08380 San Martin, 2017, Tenascin-C and integrin α9 mediate interactions of prostate cancer with the bone microenvironment, Cancer Res., 77, 5977, 10.1158/0008-5472.CAN-17-0064 Yoshida, 2015, Tenascin-C and integrins in cancer, Cell Adhes. Migrat., 9, 96, 10.1080/19336918.2015.1008332 Karkampouna, 2020, Stroma transcriptomic and proteomic profile of prostate cancer metastasis xenograft models reveals prognostic value of stroma signatures, Cancers, 12, 10.3390/cancers12123786 Gupta, 2012, Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis, Mol. Cancer, 11, 66, 10.1186/1476-4598-11-66 Gupta, 2006, Cancer metastasis: building a framework, Cell, 127, 679, 10.1016/j.cell.2006.11.001 Grindel, 2018, Matrilysin/MMP-7 cleavage of perlecan/HSPG2 complexed with semaphorin 3A supports FAK-mediated stromal invasion by prostate cancer cells, Sci. Rep., 8, 7262, 10.1038/s41598-018-25435-3 Berish, 2018, Translational models of prostate cancer bone metastasis, Nat. Rev. Urol., 15, 403, 10.1038/s41585-018-0020-2 Fornetti, 2018, Understanding the bone in cancer metastasis, J. Bone Miner. Res., 33, 2099, 10.1002/jbmr.3618 Helo, 2012, Role of denosumab in prostate cancer, Prostate Cancer Prostatic Dis., 15, 231, 10.1038/pcan.2012.2 Gartrell, 2015, Metastatic prostate cancer and the bone: significance and therapeutic options, Eur. Urol., 68, 850, 10.1016/j.eururo.2015.06.039 Ganguly, 2014, The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis, Front. Oncol., 4, 364, 10.3389/fonc.2014.00364 Weilbaecher, 2011, Cancer to bone: a fatal attraction, Nat. Rev. Cancer, 11, 411, 10.1038/nrc3055 Roato, 2013, Solid tumours show osteotropism: mechanisms of bone metastases, Clin. Rev. Bone Miner. Metabol., 11, 10.1007/s12018-013-9144-3 Coleman, 2020, Bone metastases, Nat. Rev. Dis. Prim., 6, 83, 10.1038/s41572-020-00216-3 Furesi, 2021, Emerging players in prostate cancer–bone niche communication, Trends Canc., 7, 112, 10.1016/j.trecan.2020.09.006 Moreno-Jiménez, 2020, Human and mouse bones physiologically integrate in a humanized mouse model while maintaining species-specific ultrastructure, Sci. Adv., 6, 10.1126/sciadv.abb9265 Meza-León, 2021 Peinado, 2017, Pre-metastatic niches: organ-specific homes for metastases, Nat. Rev. Cancer, 17, 302, 10.1038/nrc.2017.6 Logothetis, 2005, Osteoblasts in prostate cancer metastasis to bone, Nat. Rev. Cancer, 5, 21, 10.1038/nrc1528 Ottewell, 2016, The role of osteoblasts in bone metastasis, J. Oncol., 5, 124 Özdemir, 2014, The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches, PLoS One, 9, 10.1371/journal.pone.0114530 Hensel, 2018, Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma, Oncotarget, 9, 10.18632/oncotarget.25608 Stone, 1978, Isolation of a human prostate carcinoma cell line (DU 145), Int. J. Cancer, 21, 274, 10.1002/ijc.2910210305 Yin, 2007, Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone, Mol. Cell Biol., 27, 7538, 10.1128/MCB.00955-07 Vlaeminck-Guillem, 2018, Extracellular vesicles in prostate cancer carcinogenesis, diagnosis, and management, Front. Oncol., 8, 222, 10.3389/fonc.2018.00222 Lorenc, 2020, Exosomes in prostate cancer diagnosis, prognosis and therapy, Int. J. Mol. Sci., 21, 10.3390/ijms21062118 Adekoya, 2020, Cytokines and chemokines as mediators of prostate cancer metastasis, Int. J. Mol. Sci., 21, 10.3390/ijms21124449 Bellido, 1997, Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation, Endocrinology, 138, 3666, 10.1210/endo.138.9.5364 Dai, 2005, Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism, Cancer Res., 65, 8274, 10.1158/0008-5472.CAN-05-1891 Hall, 2006, Role of Wnts in prostate cancer bone metastases, J. Cell. Biochem., 97, 661, 10.1002/jcb.20735 Vickman, 2020, Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment, Prostate, 80, 173, 10.1002/pros.23929 Loberg, 2007, Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo, Cancer Res., 67, 9417, 10.1158/0008-5472.CAN-07-1286 Loberg, 2006, CCL2 is a potent regulator of prostate cancer cell migration and proliferation, Neoplasia, 8, 578, 10.1593/neo.06280 Probert, 2019, Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis, Oncogene, 38, 1751, 10.1038/s41388-018-0540-5 Liu, 2016, Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression, Int. J. Urol., 23, 734, 10.1111/iju.13145 Hashimoto, 2018, Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A, Proc. Natl. Acad. Sci. U. S. A., 115, 2204, 10.1073/pnas.1717363115 Morhayim, 2015, Proteomic signatures of extracellular vesicles secreted by nonmineralizing and mineralizing human osteoblasts and stimulation of tumor cell growth, Faseb. J., 29, 274, 10.1096/fj.14-261404 Henrich, 2020, Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner, J. Extracell. Vesicles, 10, 10.1002/jev2.12042 Hoshino, 2015, Tumour exosome integrins determine organotropic metastasis, Nature, 527, 329, 10.1038/nature15756 Deep, 2020, Exosomes secreted by prostate cancer cells under hypoxia promote matrix metalloproteinases activity at pre-metastatic niches, Mol. Carcinog., 59, 323, 10.1002/mc.23157 Dai, 2019, Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis, J. Exp. Med., 216, 2883, 10.1084/jem.20190158 Zayzafoon, 2004, Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines, J. Biol. Chem., 279, 3662, 10.1074/jbc.M308158200 Tyekucheva, 2017, Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer, Nat. Commun., 8, 420, 10.1038/s41467-017-00460-4 Tsunoda, 2009, The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma, Prostate, 69, 1398, 10.1002/pros.20988 Singh, 2014, Stromal androgen receptor in prostate development and cancer, Am. J. Pathol., 184, 2598, 10.1016/j.ajpath.2014.06.022 Wikström, 2009, Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients, Prostate, 69, 799, 10.1002/pros.20927 Ricciardelli, 2005, Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease, Prostate, 63, 19, 10.1002/pros.20154 Leach, 2015, Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome, Oncotarget, 6, 16135, 10.18632/oncotarget.3873 Mantalaris, 2001, Localization of androgen receptor expression in human bone marrow, J. Pathol., 193, 361, 10.1002/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W Gevaert, 2020, The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients, PLoS One, 15, 10.1371/journal.pone.0244663 Kiebish, 2020, Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer, J. Transl. Med., 18, 10, 10.1186/s12967-019-02185-y Ishii, 2018, Role of stromal paracrine signals in proliferative diseases of the aging human prostate, J. Clin. Med., 7, 68, 10.3390/jcm7040068 Kajiwara, 2020, Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure, Lab. Invest., 100, 670, 10.1038/s41374-019-0352-4 Zhang, 2020, Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer, Cancer Cell, 38, 279, 10.1016/j.ccell.2020.06.005 Cioni, 2018, Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration, Mol. Oncol., 12, 1308, 10.1002/1878-0261.12327 Placencio, 2008, Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity, Cancer Res., 68, 4709, 10.1158/0008-5472.CAN-07-6289 Ottewell, 2014, Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone, Endocr. Relat. Cancer, 21, 769, 10.1530/ERC-14-0199 van der Pluijm, 2005, Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo, Cancer Res., 65, 7682, 10.1158/0008-5472.CAN-04-4188 He, 2021, Transcriptional mediators of treatment resistance in lethal prostate cancer, Nat. Med., 27, 426, 10.1038/s41591-021-01244-6 Sun, 2012, Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B, Nat. Med., 18, 1359, 10.1038/nm.2890 Gingrich, 1996, Metastatic prostate cancer in a transgenic mouse, Cancer Res., 56, 4096 Kaplan-Lefko, 2003, Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model, Prostate, 55, 219, 10.1002/pros.10215 Garabedian, 1998, A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells, Proc. Natl. Acad. Sci. Unit. States Am., 95, 15382, 10.1073/pnas.95.26.15382 Masumori, 2001, A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential, Cancer Res., 61, 2239 Perez-Stable, 1997, Prostate cancer progression, metastasis, and gene expression in transgenic mice, Cancer Res., 57, 900 Yanagisawa, 2007, Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy, Hum. Pathol., 38, 1611, 10.1016/j.humpath.2007.04.008 Bezzi, 2018, Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms, Nat. Med., 24, 165, 10.1038/nm.4463 Morgan, 2009, Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence, Clin. Cancer Res., 15, 677, 10.1158/1078-0432.CCR-08-1754 Arriaga, 2020, A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance, Nat. Can., 1, 1082, 10.1038/s43018-020-00125-0 Aytes, 2013, ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer, Proc. Natl. Acad. Sci. U. S. A, 110, E3506, 10.1073/pnas.1303558110 Arriaga, 2019, Genetically engineered mouse models of prostate cancer in the postgenomic era, Cold Spring Harb. Perspect. Med., 9, 10.1101/cshperspect.a030528 Ding, 2012, Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases, Cell, 148, 896, 10.1016/j.cell.2012.01.039 Ittmann, 2013, Animal models of human prostate cancer: the consensus report of the New York meeting of the mouse models of human cancers consortium prostate pathology committee, Cancer Res., 73, 2718, 10.1158/0008-5472.CAN-12-4213 Ding, 2011, SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression, Nature, 470, 269, 10.1038/nature09677 Lunardi, 2013, A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer, Nat. Genet., 45, 747, 10.1038/ng.2650 Kim, 2012, A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53, Oncogene, 31, 322, 10.1038/onc.2011.236 Ellwood-Yen, 2003, Myc-driven murine prostate cancer shares molecular features with human prostate tumors, Cancer Cell, 4, 223, 10.1016/S1535-6108(03)00197-1 Simons, 2019, A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host, Oncotarget, 10, 6845, 10.18632/oncotarget.27317 Hubbard, 2016, Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer, Cancer Res., 76, 283, 10.1158/0008-5472.CAN-14-3280 Mestas, 2004, Of mice and not men: differences between mouse and human immunology, J. Immunol., 172, 2731, 10.4049/jimmunol.172.5.2731 Kerschnitzki, 2011, The organization of the osteocyte network mirrors the extracellular matrix orientation in bone, J. Struct. Biol., 173, 303, 10.1016/j.jsb.2010.11.014 Martine, 2017, Engineering a humanized bone organ model in mice to study bone metastases, Nat. Protoc., 12, 639, 10.1038/nprot.2017.002 McGovern, 2021, A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells, Commun. Biol., 1014, 10.1038/s42003-021-02527-x Bock, 2021, In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer, Sci. Adv., 7, 10.1126/sciadv.abg2564 McGovern, 2018, Humanization of the prostate microenvironment reduces homing of PC3 prostate cancer cells to human tissue-engineered bone, Cancers, 10, 10.3390/cancers10110438 Mulholland, 2012, Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells, Cancer Res., 72, 1878, 10.1158/0008-5472.CAN-11-3132 Wang, 2012, B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer, Cancer Res., 72, 4765, 10.1158/0008-5472.CAN-12-0820 Kane, 2003, Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy, Urology, 61, 607, 10.1016/S0090-4295(02)02411-1 Beyer, 2000, A combined PET/CT scanner for clinical oncology, J. Nucl. Med., 41, 1369 Hara, 1998, PET imaging of prostate cancer using carbon-11-choline, J. Nucl. Med., 39, 990 Glunde, 2011, Choline metabolism in malignant transformation, Nat. Rev. Cancer, 11, 835, 10.1038/nrc3162 Lowrance William, 2021, Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I, J. Urol., 205, 14, 10.1097/JU.0000000000001375 Bastawrous, 2014, Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice, Radiographics, 34, 1295, 10.1148/rg.345130061 Uprimny, 2018, Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy, Eur. J. Nucl. Med. Mol. Imag., 45, 1873, 10.1007/s00259-018-4048-6 Horoszewicz, 1987, Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients, Anticancer Res., 7, 927 Israeli, 1994, Expression of the prostate-specific membrane antigen, Cancer Res., 54, 1807 Israeli, 1993, Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen, Cancer Res., 53, 227 K.A.-O. Rahbar, A. Afshar-Oromieh, H. Jadvar, H. Ahmadzadehfar, PSMA Theranostics: Current Status and Future Directions. Afshar-Oromieh, 2013, PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur. J. Nucl. Med. Mol. Imag., 40, 486, 10.1007/s00259-012-2298-2 Shimkets, 2005 Sachpekidis, 2016, 68Ga-PSMA-11 dynamic PET/CT imaging in primary prostate cancer, Clin. Nucl. Med., 41, 10.1097/RLU.0000000000001349 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Calais, 2019, 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial, Lancet Oncol., 20, 1286, 10.1016/S1470-2045(19)30415-2 Alberts, 2020, PSMA-negative prostate cancer and the continued value of choline-PET/CT, Nuklearmedizin, Nucl. Med., 59, 1 Calais, 2018, 68)Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning, J. Nucl. Med., 59, 230, 10.2967/jnumed.117.201749 Grubmuller, 2018, 68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making, Eur. J. Nucl. Med. Mol. Imag., 45, 235, 10.1007/s00259-017-3858-2 Calais, 2019, Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT], BMC Cancer, 19, 18, 10.1186/s12885-018-5200-1 Alberts, 2021, Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis, Eur. J. Nucl. Med. Mol. Imag., 48, 2978, 10.1007/s00259-021-05210-9 Frangos, 2019, Why should we be concerned about a “g”, Eur. J. Nucl. Med. Mol. Imag., 46, 519, 10.1007/s00259-018-4204-z Sartor, 2014, Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial, Lancet Oncol., 15, 738, 10.1016/S1470-2045(14)70183-4 Kratochwil, 2019, EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT), Eur. J. Nucl. Med. Mol. Imag., 46, 2536, 10.1007/s00259-019-04485-3 Fanti, 2018, Consensus on molecular imaging and theranostics in prostate cancer, Lancet Oncol., 19, e696, 10.1016/S1470-2045(18)30604-1 Gallicchio, 2014, Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain, J. Bone Miner. Metabol., 32, 434, 10.1007/s00774-013-0507-0 Nilsson, 2012, A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer, Eur. J. Cancer, 48, 678, 10.1016/j.ejca.2011.12.023 Poeppel, 2018, EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer, Eur. J. Nucl. Med. Mol. Imag., 45, 824, 10.1007/s00259-017-3900-4 Morris, 2019, Radium-223 mechanism of action: implications for use in treatment combinations, Nat. Rev. Urol., 16, 745, 10.1038/s41585-019-0251-x Hoskin, 2014, Lancet Oncol., 15, 1397, 10.1016/S1470-2045(14)70474-7 Skelton, 2020, A single-center retrospective analysis of the effect of radium-223 (Xofigo) on pancytopenia in patients with metastatic castration-resistant prostate cancer, Cureus, 12, e6806 Afshar-Oromieh, 2017, Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095, Eur. J. Nucl. Med. Mol. Imag., 44, 950, 10.1007/s00259-017-3665-9 Rahbar, 2017, German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients, J. Nucl. Med., 58, 85, 10.2967/jnumed.116.183194 Hofman, 2021, [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial, Lancet, 397, 797, 10.1016/S0140-6736(21)00237-3 Nervi, 2009, Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100, Blood, 113, 6206, 10.1182/blood-2008-06-162123 US National Library of Medicine Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 US National Library of Medicine Yumoto, 2016, Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow, Sci. Rep., 6, 36520, 10.1038/srep36520 Rucci, 2018, Osteomimicry: how the seed grows in the soil, Calcif. Tissue Int., 10.1007/s00223-017-0365-1